MCQ Quiz: Renal Failure & Disease

Renal failure and disease are critical health issues that profoundly impact medication therapy management. Pharmacists must possess a deep understanding of both Acute Kidney Injury (AKI) and the progressive nature of Chronic Kidney Disease (CKD), as detailed in the Patient Care 4 curriculum’s comprehensive “Renal System” module. This quiz will test your knowledge on the pathophysiology, staging, and evidence-based management of various renal diseases and their myriad complications, preparing you for this vital area of pharmacy practice.

1. An abrupt decline in kidney function characterized by a rise in serum creatinine and/or a decrease in urine output is known as:

  • a. Chronic Kidney Disease (CKD)
  • b. End-Stage Renal Disease (ESRD)
  • c. Acute Kidney Injury (AKI)
  • d. Nephrotic Syndrome

Answer: c. Acute Kidney Injury (AKI)

2. Which type of AKI is caused by a sudden drop in blood flow to the kidneys?

  • a. Prerenal
  • b. Intrinsic
  • c. Postrenal
  • d. Intrarenal

Answer: a. Prerenal

3. The two most common causes of Chronic Kidney Disease (CKD) in the United States are:

  • a. Smoking and hyperlipidemia
  • b. Diabetes and hypertension
  • c. Polycystic kidney disease and glomerulonephritis
  • d. Recurrent kidney stones and infections

Answer: b. Diabetes and hypertension

4. According to the KDIGO guidelines, CKD is staged based on the patient’s GFR and what other laboratory marker?

  • a. Serum potassium
  • b. Hemoglobin
  • c. Albuminuria
  • d. Serum phosphate

Answer: c. Albuminuria

5. Which class of medications is recommended first-line to slow the progression of diabetic kidney disease, particularly in patients with albuminuria?

  • a. Beta-blockers
  • b. Calcium channel blockers
  • c. ACE Inhibitors or ARBs
  • d. Loop diuretics

Answer: c. ACE Inhibitors or ARBs

6. The “Pathophysiology and Management of Acute Kidney Injury (AKI)” is a specific learning module in which course?

  • a. PHA5784C Patient Care 4
  • b. PHA5104 Sterile Compounding
  • c. PHA5703 Pharmacy Law and Ethics
  • d. PHA5878C Patient Care 3

Answer: a. PHA5784C Patient Care 4

7. Anemia of CKD is primarily caused by a deficiency of:

  • a. Iron
  • b. Vitamin B12
  • c. Erythropoietin (EPO)
  • d. Folic acid

Answer: c. Erythropoietin (EPO)

8. Before initiating an erythropoiesis-stimulating agent (ESA) for anemia of CKD, the pharmacist must ensure the patient has:

  • a. Adequate iron stores.
  • b. A very high hemoglobin level.
  • c. Uncontrolled blood pressure.
  • d. A low serum potassium level.

Answer: a. Adequate iron stores.

9. Acute Tubular Necrosis (ATN) caused by a nephrotoxic drug like an aminoglycoside is what type of AKI?

  • a. Prerenal
  • b. Intrinsic
  • c. Postrenal
  • d. Functional

Answer: b. Intrinsic

10. A patient with an enlarged prostate causing a urinary obstruction develops an AKI. This is classified as:

  • a. Prerenal
  • b. Intrinsic
  • c. Postrenal
  • d. Vasomotor

Answer: c. Postrenal

11. The “Pathophysiology and Management of Chronic Kidney Disease (CKD)” is a topic covered in the Patient Care 4 curriculum.

  • a. True
  • b. False

Answer: a. True

12. The management of CKD-Mineral and Bone Disorder (CKD-MBD) involves:

  • a. Lowering serum phosphate with phosphate binders.
  • b. Managing secondary hyperparathyroidism with Vitamin D analogs or calcimimetics.
  • c. Maintaining calcium homeostasis.
  • d. All of the above.

Answer: d. All of the above.

13. A patient is prescribed sevelamer for hyperphosphatemia. The pharmacist should counsel the patient to take this medication:

  • a. On an empty stomach.
  • b. With meals to bind dietary phosphate.
  • c. At bedtime.
  • d. Once a week.

Answer: b. With meals to bind dietary phosphate.

14. Which of the following is an “alarm symptom” in a patient at risk for AKI?

  • a. Normal urine output.
  • b. A sudden, significant decrease in urine output (oliguria).
  • c. Mild fatigue.
  • d. A stable serum creatinine.

Answer: b. A sudden, significant decrease in urine output (oliguria).

15. How do NSAIDs cause drug-induced kidney disease?

  • a. They cause vasodilation of the efferent arteriole.
  • b. They cause direct tubular necrosis.
  • c. They inhibit prostaglandin synthesis, leading to vasoconstriction of the afferent arteriole.
  • d. They cause an allergic reaction in the interstitium.

Answer: c. They inhibit prostaglandin synthesis, leading to vasoconstriction of the afferent arteriole.

16. The “Management of Drug-Induced Kidney Disease” is an active learning session in the Patient Care 4 course.

  • a. True
  • b. False

Answer: a. True

17. What is the GFR range for Stage 5 CKD (End-Stage Renal Disease)?

  • a. > 90 mL/min/1.73m²
  • b. 60-89 mL/min/1.73m²
  • c. 30-59 mL/min/1.73m²
  • d. < 15 mL/min/1.73m²

Answer: d. < 15 mL/min/1.73m²

18. The cornerstone of management for prerenal AKI is:

  • a. Starting a potent diuretic.
  • b. Restoring renal perfusion with IV fluids or by treating the underlying cause of hypoperfusion.
  • c. Initiating dialysis immediately.
  • d. Administering an NSAID.

Answer: b. Restoring renal perfusion with IV fluids or by treating the underlying cause of hypoperfusion.

19. A patient with CKD is at high risk for which electrolyte abnormality?

  • a. Hypokalemia
  • b. Hyperkalemia
  • c. Hypophosphatemia
  • d. Hypernatremia

Answer: b. Hyperkalemia

20. The curriculum includes a module on the “Renal System” in Patient Care 4.

  • a. True
  • b. False

Answer: a. True

21. Acute Interstitial Nephritis (AIN) is a type of intrinsic AKI most often caused by:

  • a. Dehydration
  • b. A hypersensitivity reaction to a drug (e.g., a beta-lactam or PPI).
  • c. An enlarged prostate.
  • d. Sepsis.

Answer: b. A hypersensitivity reaction to a drug (e.g., a beta-lactam or PPI).

22. Which of the following is NOT a primary goal of CKD management?

  • a. Curing the kidney disease.
  • b. Slowing the progression of kidney damage.
  • c. Managing comorbidities like hypertension and diabetes.
  • d. Treating complications like anemia and CKD-MBD.

Answer: a. Curing the kidney disease.

23. Why is it important to adjust the doses of many medications in patients with renal failure?

  • a. To increase their effectiveness.
  • b. To prevent the accumulation of the drug or its metabolites, leading to toxicity.
  • c. Because all drugs are cleared by the kidneys.
  • d. To make the drugs cheaper.

Answer: b. To prevent the accumulation of the drug or its metabolites, leading to toxicity.

24. An active learning session on AKI and CKD is part of the Patient Care 4 curriculum.

  • a. True
  • b. False

Answer: a. True

25. A patient with diabetic nephropathy is started on lisinopril. A small, initial increase in serum creatinine (e.g., up to 30%) is:

  • a. A sign of acute renal failure requiring immediate discontinuation of the drug.
  • b. An expected hemodynamic effect that indicates the drug is working to reduce glomerular pressure.
  • c. A reason to double the dose of lisinopril.
  • d. An indication for starting dialysis.

Answer: b. An expected hemodynamic effect that indicates the drug is working to reduce glomerular pressure.

26. Which of the following is a symptom of uremia in a patient with ESRD?

  • a. High energy levels
  • b. Nausea, fatigue, and metallic taste
  • c. Increased appetite
  • d. Normal skin color

Answer: b. Nausea, fatigue, and metallic taste

27. The primary treatment for postrenal AKI is:

  • a. IV fluids
  • b. Diuretics
  • c. Relieving the source of the obstruction.
  • d. An ACE inhibitor.

Answer: c. Relieving the source of the obstruction.

28. An active learning session on the renal system is part of which course?

  • a. PHA5784C Patient Care 4
  • b. PHA5163L Professional Skills Lab 3
  • c. PHA5781 Patient Care I
  • d. PHA5782C Patient care 2

Answer: a. PHA5784C Patient Care 4

29. ESAs like epoetin alfa should not be initiated until the hemoglobin is below what level in CKD patients?

  • a. 13 g/dL
  • b. 12 g/dL
  • c. 11 g/dL
  • d. 10 g/dL

Answer: d. 10 g/dL

30. The “Dosing in Renal Dysfunction” is a core module in the Drug Therapy Individualization course.

  • a. True
  • b. False

Answer: a. True

31. A patient with CKD and hyperkalemia should be counseled to avoid:

  • a. High-potassium foods like bananas and oranges.
  • b. Salt substitutes containing potassium chloride.
  • c. NSAIDs.
  • d. All of the above.

Answer: d. All of the above.

32. What is the definition of microalbuminuria?

  • a. Urine albumin-to-creatinine ratio (UACR) < 30 mg/g
  • b. UACR 30-300 mg/g
  • c. UACR > 300 mg/g
  • d. No albumin in the urine.

Answer: b. UACR 30-300 mg/g

33. What is the role of a pharmacist in preventing drug-induced kidney disease?

  • a. Screening for high-risk patients and high-risk drugs.
  • b. Recommending appropriate hydration.
  • c. Monitoring renal function during therapy with nephrotoxic agents.
  • d. All of the above.

Answer: d. All of the above.

34. The term “nephrotoxic” refers to a substance that is:

  • a. Beneficial to the kidneys.
  • b. Excreted by the kidneys.
  • c. Toxic or damaging to the kidneys.
  • d. Metabolized by the kidneys.

Answer: c. Toxic or damaging to the kidneys.

35. A patient with CKD Stage 4 has:

  • a. Normal kidney function.
  • b. Mildly decreased kidney function.
  • c. Moderately decreased kidney function.
  • d. Severely decreased kidney function.

Answer: d. Severely decreased kidney function.

36. A patient is receiving IV contrast for a CT scan. A preventative strategy for contrast-induced nephropathy is:

  • a. Administering an NSAID before the scan.
  • b. Restricting fluids.
  • c. IV hydration with normal saline before and after the scan.
  • d. Administering a diuretic after the scan.

Answer: c. IV hydration with normal saline before and after the scan.

37. Which of the following is NOT a complication of CKD?

  • a. Anemia
  • b. Mineral and Bone Disorder
  • c. Cardiovascular Disease
  • d. Improved medication clearance

Answer: d. Improved medication clearance

38. The principle of renal clearance is a major topic in the Drug Therapy Individualization course.

  • a. True
  • b. False

Answer: a. True

39. Management of a patient with AKI includes:

  • a. Discontinuing all potentially nephrotoxic medications.
  • b. Adjusting the doses of all renally cleared medications.
  • c. Monitoring fluid status and electrolytes closely.
  • d. All of the above.

Answer: d. All of the above.

40. An active learning session covering AKI and CKD is part of which course module?

  • a. Module 7: Renal System
  • b. Module 1: PUD and GERD
  • c. Module 4: Gastrointestinal Infections
  • d. Module 5: Nutrition & Weight Management

Answer: a. Module 7: Renal System

41. The most common cause of intrinsic AKI in hospitalized patients is:

  • a. Glomerulonephritis
  • b. Acute Interstitial Nephritis (AIN)
  • c. Acute Tubular Necrosis (ATN)
  • d. Vasculitis

Answer: c. Acute Tubular Necrosis (ATN)

42. Which of the following can cause prerenal AKI?

  • a. Sepsis leading to hypotension.
  • b. Heart failure with low cardiac output.
  • c. Severe volume depletion from vomiting.
  • d. All of the above.

Answer: d. All of the above.

43. The progression of CKD can be slowed by:

  • a. Strict blood pressure control.
  • b. Strict glycemic control in diabetic patients.
  • c. Use of ACE inhibitors or ARBs in patients with proteinuria.
  • d. All of the above.

Answer: d. All of the above.

44. A patient is taking metformin and their eGFR drops to 25 mL/min/1.73m². The pharmacist should recommend:

  • a. Increasing the metformin dose.
  • b. Continuing the current dose.
  • c. Discontinuing the metformin.
  • d. Adding a second diabetes medication.

Answer: c. Discontinuing the metformin.

45. Which of the following is a common cause of drug-induced acute interstitial nephritis (AIN)?

  • a. Acetaminophen
  • b. Penicillins and NSAIDs
  • c. Digoxin
  • d. Metformin

Answer: b. Penicillins and NSAIDs

46. End-Stage Renal Disease (ESRD) is defined as:

  • a. CKD Stage 3
  • b. CKD Stage 4
  • c. CKD requiring dialysis or kidney transplantation.
  • d. Any form of AKI.

Answer: c. CKD requiring dialysis or kidney transplantation.

47. A BUN:SCr ratio > 20:1 suggests:

  • a. Postrenal obstruction
  • b. A prerenal cause or dehydration
  • c. Intrinsic kidney damage
  • d. A normal state

Answer: b. A prerenal cause or dehydration

48. An active learning session on renal failure is part of which course?

  • a. PHA5784C Patient Care 4
  • b. PHA5163L Professional Skills Lab 3
  • c. PHA5781 Patient Care I
  • d. PHA5782C Patient Care 2

Answer: a. PHA5784C Patient Care 4

49. The presence of “muddy brown casts” in the urine is pathognomonic for:

  • a. Acute Tubular Necrosis (ATN)
  • b. Prerenal AKI
  • c. Postrenal AKI
  • d. Normal urine

Answer: a. Acute Tubular Necrosis (ATN)

50. The ultimate goal of understanding renal failure and disease is to:

  • a. Memorize all the stages of CKD.
  • b. Prevent, slow the progression of, and manage the complications of kidney disease through safe and effective medication therapy.
  • c. Be able to dose all drugs without a calculator.
  • d. Qualify to perform dialysis.

Answer: b. Prevent, slow the progression of, and manage the complications of kidney disease through safe and effective medication therapy.

Leave a Comment